Blood Test Shows Promise in Predicting Dementia Risk in Women Decades Before Symptoms
A new study suggests a simple blood test may predict the risk of dementia in women up to 25 years before symptoms appear, potentially opening the door to earlier prevention strategies. Researchers at the University of California San Diego have identified a protein biomarker that shows a strong association with the future development of cognitive decline.
Study Details
The research, published recently, analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study, a long-term study that began in the late 1990s. Participants, aged 65 to 79 at the study’s outset, showed no signs of cognitive impairment when the study began . Over a follow-up period of up to 25 years, researchers found that elevated levels of the biomarker p-tau217 were strongly linked to an increased risk of developing mild cognitive impairment or dementia.
Identifying Risk Years in Advance
Dr. Aladdin Shadyab, associate professor of public health and medicine at the University of California San Diego, and lead author of the study, explained that the findings suggest the possibility of predicting dementia risk nearly two decades before symptoms manifest through a simple blood test in older women . These biomarkers could help identify individuals at higher risk and facilitate the development of strategies to delay or prevent the onset of the disease.
How the Biomarker Works
The biomarker, p-tau217, is a protein linked to the brain changes seen in Alzheimer’s disease . Higher levels of this protein in the blood correlated with a greater likelihood of developing dementia later in life. Early detection could allow for the implementation of health monitoring programs and preventive interventions before memory problems significantly impact daily life.
Variations in Risk Among Women
The study revealed that the relationship between p-tau217 levels and dementia risk wasn’t uniform across all women. Women over 70 with high levels of the biomarker were more susceptible to cognitive decline than younger women. The effect was also more pronounced in women carrying the APOE ε4 gene, a known genetic risk factor for Alzheimer’s disease. The biomarker was a stronger predictor of dementia in women who had received hormone therapy containing estrogen and progestin compared to those who received a placebo.
The Potential of Blood-Based Testing
Researchers believe blood-based tests like the p-tau217 assessment offer significant advantages over other methods, such as brain imaging or spinal fluid analysis, due to their less invasive nature and ease of administration . This could accelerate research into dementia risk factors and the evaluation of potential preventive strategies.
Ongoing Research and Future Directions
While the results are promising, researchers emphasize that blood tests for Alzheimer’s detection are still under investigation and are not currently recommended for routine screening in individuals without symptoms. Further studies are needed before widespread medical utilize, particularly as the current study focused solely on older women, meaning the findings may not be generalizable to men or younger populations.
Future research will focus on understanding the influence of other factors, such as genetics, hormonal treatments, and age-related diseases, on the biomarker and its predictive role in dementia.
UC San Diego Alzheimer’s Research
This research builds on the ongoing work at the UC San Diego Shiley-Marcos Alzheimer’s Disease Research Center, dedicated to understanding the causes, clinical features, and treatments for Alzheimer’s disease and related memory disorders . The Xu Chen Lab at UCSD also focuses on Alzheimer’s disease research, investigating the causes and potential treatments for the disease .